High Cardiac Risk of E-cigarettes: Russian Expert

Industry Insight by 2FIRSTS.ai
Dec.06.2023
High Cardiac Risk of E-cigarettes: Russian Expert
E-cigarette use increases cardiovascular disease risk, raises the chance of heart attacks and strokes by 56% and 33% respectively, warns Russian expert.

According to recent news from A42.RU, Dr. Aleksey Alekseyevichkov, head of cardiology at Kuzbass, Russia, and a candidate for medical science, has stated that e-cigarettes are extremely harmful, including a significant increase in the risk of cardiovascular diseases.

 

He emphasized that e-cigarettes are more likely to cause heart disease and stroke compared to regular cigarettes, with users facing a 56% increased risk of heart attacks and a one-third increased risk of stroke.

 

According to Alekseyevko, e-cigarette use can lead to the loss of elasticity in blood vessel walls, affecting oxygen supply and making users more prone to symptoms such as irregular heartbeat, chest pain, and rapid heart rate. Additionally, toxic substances produced by e-cigarettes can increase the risk of blood clotting and arterial hardening, with higher risk observed among women.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Russia proposes extending voluntary labeling pilot for reusable e-cigarettes to Aug. 31, 2026
Russia proposes extending voluntary labeling pilot for reusable e-cigarettes to Aug. 31, 2026
Russia’s Ministry of Industry and Trade has proposed extending a voluntary labeling pilot covering reusable e-cigarettes and similar personal electric vaporizing devices until August 31, 2026. A draft government decree has been published on the unified portal for posting drafts of normative legal acts.
Jan.22 by 2FIRSTS.ai
2Firsts Breaking | FDA to Hold PMTA Roundtable for Small ENDS Manufacturers, Spotlighting Small Business Applications
2Firsts Breaking | FDA to Hold PMTA Roundtable for Small ENDS Manufacturers, Spotlighting Small Business Applications
The FDA’s Center for Tobacco Products (CTP) will hold a PMTA roundtable on February 10, 2026, for small electronic nicotine delivery systems (ENDS) manufacturers, seeking input on PMTA submission experiences and recommendations for streamlining and improving the review process.
Dec.24
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
As regulation tightens and innovation matures, competition in the new tobacco industry is shifting. In its 2026 Global Product Trends in the New Tobacco Industry report, 2Firsts examines how heated tobacco, nicotine pouches, and vape products are moving beyond feature-driven upgrades toward system-level design, where experience management, compliance structure, and engineering capability increasingly shape long-term competition.
Jan.13 by 2Firsts Perspectives
China’s Nov. Vape Exports to U.S. Hold at $549 Million, Sustaining High After October’s $591 Million Peak
China’s Nov. Vape Exports to U.S. Hold at $549 Million, Sustaining High After October’s $591 Million Peak
China’s Nov. vape exports to the U.S. held at $549 million, following October’s $591 million record. 2025 YTD exports reached $3.72 billion, officially eclipsing 2024’s full-year total. This $1.14 billion 60-day surge signals a critical inventory overhang, heightening financial and regulatory risks for manufacturers.
Dec.22
BAT Expects Around 2% Revenue and Operating Profit Growth in FY25
BAT Expects Around 2% Revenue and Operating Profit Growth in FY25
British American Tobacco (BAT) reaffirmed its 2026 guidance while announcing a £1.3 billion (approximately USD 1.65 billion) share buyback for FY26. The company expects around 2% growth in revenue and adjusted profit from operations for FY25. Accelerating New Category growth, driven by Velo Plus and improving U.S. Vuse performance, is expected to deliver double-digit H2 revenue growth.
Dec.09 by 2FIRSTS.ai
Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review
Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review
Altria on December 19 confirmed that six on! PLUS nicotine pouch products had received U.S. FDA marketing authorization, ending a PMTA review lasting more than a year after the company moved ahead with launch plans before clearance.
Regulations
Dec.20